Scores and assessments of recently awarded proposals

Pikado BV contributed to the preparation of research proposals of exceptional quality with excellent scoring and assessments by independent reviewers.

H2020 848166 | ISOLDA (Innovative Vaccination Strategies for Older Adults) | 2020-2025 | >6 Mi €

Score of 13 / 15 | Excellence 4.5/5 “very good and ambitious proposal”; Impact 4/5 “very good application with highly justified impacts”; Implementation 4.5/5 “very good work-plan”

 H2020 874650 | ENDFLU (Evaluation of Rationally Designed Influenza Vaccines) | 2020-2025 | >8 Mi €

Score of 14 / 15 | Excellence 4.5/5 “well-constructed, ambitious and thoughtful interdisciplinary approach”; Impact 4.5/5 “major impact”; Implementation 5/5 “work plan is well defined […] proposal is well constructed, well thought out”

H2020 101003651 | MANCO (Monoclonal antibodies against 2019-New Coronavirus | 2020-2022 | >3 Mi €

Score of 14.5 / 15 | Excellence 5/5 “excellent and go clearly beyond the state-of-the-art”; Impact 4.5/5 “great impact […] well described and appropriate”; Implementation 5/5 “work plan of exceptional quality”

IMI 101005077 | CARE (Corona Accelerated R&D in Europe) | 2020-2025 | >36 Mi €

Score of 14 / 15 | Excellence 5/5 “objectives are clearly presented and pertinent […] rationale is well-developed”; Impact 4.5/5 “proposal presents clearly and convincingly its contribution”; Implementation 4.5/5 “well-structured […] well aligned with the goals”.